Lightnews — Scholar-powered news

pharmaphorum

@pharmaphorum.bsky.social

In what is thought to be the first major pharma #M&A deal of the year, #Amgen has bought Oxford, UK-based #biotech #DarkBlueTherapeutics (DBT), which specialises in #cancer therapies.

pharmaphorum.com/news/amgen-i...

Amgen inks $840m takeover of UK's Dark Blue Therapeutics

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

pharmaphorum.com

January 6, 2026 at 6:00 PM

pharmaphorum

@pharmaphorum.bsky.social

For a second time, #EliLilly has turned to Boston biotech #NimbusTherapeutics to add a potential #weightloss therapy to its pipeline.

pharmaphorum.com/news/lilly-t...

Lilly taps Nimbus for another obesity candidate

For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline.

pharmaphorum.com

January 6, 2026 at 5:55 PM

pharmaphorum

@pharmaphorum.bsky.social

#Alumis is preparing to file its oral #TYK2inhibitor envudeucitinib as a treatment for #psoriasis later this year, after a pair of positive phase 3 trials.

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

buff.ly

January 6, 2026 at 4:30 PM

pharmaphorum

@pharmaphorum.bsky.social

#NHSEngland has said that the new #onlinehospital, due to launch next year, will focus initially on nine common conditions, including #menopause and #prostate health.

More details emerge of NHS online hospital due next year

The NHS Online hospital, due to launch next year, will focus initially on nine common conditions, including menopause and prostate health.

buff.ly

January 6, 2026 at 3:30 PM

pharmaphorum

@pharmaphorum.bsky.social

Chinese #RNA-based medicine developer Suzhou #Ribo Life Science has filed a #HongKong #IPO, aiming to raise new funds for its lead RBD4059 drug candidate for #thromboticdiseases.

RNA specialist Ribo files $205m IPO in Hong Kong

Chinese RNA-based medicine developer Ribo has filed a Hong Kong IPO to raise cash for its siRNA drug for thrombotic diseases.

buff.ly

January 6, 2026 at 2:15 PM

pharmaphorum

@pharmaphorum.bsky.social

The #CDC has upended the #childhoodvaccination schedule, cutting the number of recommended #immunisations in a move that the #Trump administration says brings the US into line with the practice in Denmark.

pharmaphorum.com/news/cdc-cut...

January 6, 2026 at 1:39 PM

pharmaphorum

@pharmaphorum.bsky.social

US biotech #AktisOncology has filed IPO documents with the Securities and Exchange Commission (#SEC), in what could be the first #biotech listing on the #Nasdaq in 2026.

pharmaphorum.com/news/aktis-o...

January 5, 2026 at 2:28 PM

pharmaphorum

@pharmaphorum.bsky.social

Fresh from its IPO at the end of last year, #InsilicoMedicine has added to its stable of partners after signing a new #alliance with #Servier that could be worth up to $888 million.

pharmaphorum.com/news/insilic...

Insilico adds Sanofi to partnership roster with $888m deal

Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.

pharmaphorum.com

January 5, 2026 at 1:23 PM

pharmaphorum

@pharmaphorum.bsky.social

#GSK has claimed an important new approval for #Nucala in chronic obstructive pulmonary disease (#COPD), in #China, which is estimated to account for around a quarter of the #globalpatientpopulation.

pharmaphorum.com/news/china-c...

China clears GSK's Nucala for COPD

GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.

pharmaphorum.com

January 5, 2026 at 12:31 PM

pharmaphorum

@pharmaphorum.bsky.social

#Sanofi could be months away from wider US approval for #Tzield, its first-in-class drug for delaying the progression of #type1diabetes (T1D), in #children as young as one.

pharmaphorum.com/news/sanofi-...

Sanofi seeks use of type 1 diabetes drug in younger kids

Sanofi could be months away from wider US approval for Tzield, its drug for delaying the progression of type 1 diabetes, in children as young as one.

pharmaphorum.com

January 5, 2026 at 11:10 AM

pharmaphorum

@pharmaphorum.bsky.social

#NovoNordisk has wasted no time in launching its oral version of the weight loss drug #Wegovy in the US after its approval by the FDA, as 2025 drew to a close.

pharmaphorum.com/news/novo-no...

Novo Nordisk launches Wegovy pill at $149 a month

Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.

pharmaphorum.com

January 5, 2026 at 10:33 AM

pharmaphorum

@pharmaphorum.bsky.social

#NICE has said #Biogen's Tysabri can now be used by the #NHS in England and Wales to treat highly active relapsing-remitting #multiplesclerosis (MS), along with a lower-cost #biosimilar version of the drug.

NICE recommends wider use of Biogen MS drug via NHS

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

buff.ly

January 2, 2026 at 4:00 PM

pharmaphorum

@pharmaphorum.bsky.social

#NovoNordisk has been handed a crucial legal win by #China's Supreme Court, which has upheld the company's #patent protection on #GLP1 agonist #semaglutide used for #diabetes and #weightloss.

pharmaphorum.com/news/china-d...

January 2, 2026 at 2:20 PM

pharmaphorum

@pharmaphorum.bsky.social

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to #CorceptTherapeutics with a decision not to approve #relacorilant, a drug for a rare #hormonaldisorder that causes #highbloodpressure.

FDA declines to approve Corcept's rare disorder drug

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.

buff.ly

January 2, 2026 at 12:30 PM

pharmaphorum

@pharmaphorum.bsky.social

Denmark's #Genmab has decided not to continue the development of a drug for #cancer, acasunlimab, which had reached phase 3 testing, after a #review of its medicines #pipeline.

pharmaphorum.com/news/genmab-...

January 2, 2026 at 11:21 AM

pharmaphorum

@pharmaphorum.bsky.social

The FDA's usual end-of-year flurry of #regulatoryapprovals is a little lighter than usual, but the agency has delivered some end-of-year cheer to #VandaPharma after giving the go-ahead to its drug for #motionsickness.

pharmaphorum.com/news/vanda-e...

Vanda ends 40-year hiatus for new motion sickness drugs

The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.

pharmaphorum.com

January 2, 2026 at 11:01 AM

pharmaphorum

@pharmaphorum.bsky.social

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

Insilico ends 2025 with $293m Hong Kong IPO

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m

pharmaphorum.com

December 31, 2025 at 1:16 PM

pharmaphorum

@pharmaphorum.bsky.social

Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.

Ultragenyx, Mereo's brittle bone drug flames out in trials

Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives

pharmaphorum.com

December 30, 2025 at 4:34 PM

pharmaphorum

@pharmaphorum.bsky.social

A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.

Judge blocks HHS' 340B rebate pilot at 11th hour

A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January

pharmaphorum.com

December 30, 2025 at 12:41 PM

pharmaphorum

@pharmaphorum.bsky.social

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.

J&J abandons trial of atopic dermatitis drug

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal

pharmaphorum.com

December 29, 2025 at 6:14 PM

pharmaphorum

@pharmaphorum.bsky.social

FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026. pharmaphorum.com/news/no-chri...